For patients with previously untreated chronic lymphocytic leukemia (CLL), fixed-duration acalabrutinib-venetoclax with or without obinutuzumab significantly prolongs progression-free survival ...

Mumbai: Pharma major, Cipla, has received final approval from the United States Food and Drug Administration (USFDA) for the New Drug Application (‘NDA’) submitted for ‘Nilotinib Capsules 50, ...

Cipla announced that it has received final approval from the United States Food and Drug Administration (USFDA) for the new drug application (NDA) submitted for 'Nilotinib Capsules 50, 150 and 200 mg' ...

In a press release issued after market hours on February 20, Cipla announced that it has received approval for Nilotinib ...

Nilotinib is an FDA approved drug used for the treatment of Philadelphia Chromosome Positive CML, which is a cancer of blood ...

From crippling fatigue to brain fog, CML treatment can affect your body in ways that go beyond the usual side effects.

Cipla has received final US FDA approval for its Nilotinib Capsules (50 mg, 150 mg, 200 mg) for the treatment of Philadelphia ...